370 related articles for article (PubMed ID: 15584653)
1. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
[TBL] [Abstract][Full Text] [Related]
2. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma.
Macwhinnie N; Monaghan H
Int J Gynecol Cancer; 2004; 14(5):938-46. PubMed ID: 15361207
[TBL] [Abstract][Full Text] [Related]
3. Immunoexpression of the PTEN protein and matrix metalloproteinase-2 in endometrial cysts, endometrioid and clear cell ovarian cancer.
Brucka A; Szyłło K
Ginekol Pol; 2013 May; 84(5):344-51. PubMed ID: 23819399
[TBL] [Abstract][Full Text] [Related]
4. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
5. [PTEN coding product: a marker for tumorigenesis and progression of endometrial carcinoma].
Gao QL; Ye F; Li J; Xing H; Lu YP; Ma D
Ai Zheng; 2003 Jun; 22(6):640-4. PubMed ID: 12948417
[TBL] [Abstract][Full Text] [Related]
6. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
[TBL] [Abstract][Full Text] [Related]
7. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.
Mutter GL; Lin MC; Fitzgerald JT; Kum JB; Baak JP; Lees JA; Weng LP; Eng C
J Natl Cancer Inst; 2000 Jun; 92(11):924-30. PubMed ID: 10841828
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
9. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.
Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H
J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303
[TBL] [Abstract][Full Text] [Related]
10. Expression of PTEN in endometrial liquid-based cytology.
Di Lorito A; Zappacosta R; Capanna S; Gatta DM; Rosini S; Schmitt FC
Acta Cytol; 2014; 58(5):495-500. PubMed ID: 25358681
[TBL] [Abstract][Full Text] [Related]
11. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
12. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
13. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression.
Baak JP; Van Diermen B; Steinbakk A; Janssen E; Skaland I; Mutter GL; Fiane B; Løvslett K
Hum Pathol; 2005 May; 36(5):555-61. PubMed ID: 15948123
[TBL] [Abstract][Full Text] [Related]
14. Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases.
Němejcová K; Rosmusová J; Bártů M; Důra M; Tichá I; Dundr P
Int J Surg Pathol; 2017 Aug; 25(5):389-396. PubMed ID: 28381136
[TBL] [Abstract][Full Text] [Related]
15. Utility of PTEN expression of endometrial "surface epithelial changes" and underlying atypical endometrial hyperplasia.
Quddus MR; Ologun BA; Sung CJ; Steinhoff MM; Lawrence WD
Int J Gynecol Pathol; 2009 Sep; 28(5):471-6. PubMed ID: 19696618
[TBL] [Abstract][Full Text] [Related]
16. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
18. Involution of PTEN-null endometrial glands with progestin therapy.
Zheng W; Baker HE; Mutter GL
Gynecol Oncol; 2004 Mar; 92(3):1008-13. PubMed ID: 14984979
[TBL] [Abstract][Full Text] [Related]
19. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression.
Salvesen HB; Stefansson I; Kretzschmar EI; Gruber P; MacDonald ND; Ryan A; Jacobs IJ; Akslen LA; Das S
Int J Oncol; 2004 Dec; 25(6):1615-23. PubMed ID: 15547698
[TBL] [Abstract][Full Text] [Related]
20. Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma.
Xiong Y; Xiong YY; Zhou YF
Eur J Gynaecol Oncol; 2010; 31(2):160-4. PubMed ID: 20527231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]